Clonazepam
Clonazepam, Klonopin (clonazepam) is a small molecule pharmaceutical. Clonazepam was first approved as Klonopin on 1982-01-01. It is used to treat absence epilepsy, bipolar disorder, dysarthria, lennox gastaut syndrome, and myoclonic epilepsies amongst others in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit alpha-3, and gamma-aminobutyric acid receptor subunit alpha-2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Clonazepam, Klonopin (discontinued: Clonazepam, Klonopin, Klonopin rapidly disintegrating)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clonazepam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KLONOPIN | CHEPLAPHARM Arzneimittel | N-017533 RX | 1982-01-01 | 3 products, RLD |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clonazepam | ANDA | 2024-11-06 |
| klonopin | New Drug Application | 2023-12-07 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 1 | 1 | 4 | 2 | 9 |
| Burning mouth syndrome | D002054 | EFO_1000850 | — | 1 | 1 | 1 | 3 | 2 | 8 |
| Burns | D002056 | — | T30.0 | 1 | 1 | 1 | 3 | 2 | 8 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 2 | 3 | 1 | 7 |
| Depression | D003863 | — | F33.9 | — | — | 1 | 3 | — | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 2 | — | 1 | 1 | 4 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | 1 | 1 | 3 | — | 4 |
| Drug resistant epilepsy | D000069279 | — | — | — | — | — | 2 | 1 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 2 | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | 1 | — | 2 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | HP_0002069 | G40.4 | — | 1 | 1 | — | 2 | 4 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | — | 2 | — | 1 | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | 1 | 2 |
| Tuberous sclerosis | D014402 | HP_0009720 | Q85.1 | — | — | 1 | — | — | 1 |
| Sclerosis | D012598 | — | — | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Epilepsia partialis continua | D017036 | EFO_1000924 | G40.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | 1 | 3 |
| Neuralgia | D009437 | EFO_0009430 | — | 2 | 1 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | 1 | — | — | — | 1 |
| Glossalgia | D005926 | — | K14.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
| Febrile seizures | D003294 | HP_0002373 | R56.0 | — | — | — | — | 1 | 1 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clonazepam |
| INN | clonazepam |
| Description | Clonazepam is 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation. It has a role as an anticonvulsant, a GABA modulator and an anxiolytic drug. It is a 1,4-benzodiazepinone and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | antianxiety agents (diazepam type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1 |
Identifiers
| PDB | — |
| CAS-ID | 1622-61-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL452 |
| ChEBI ID | 3756 |
| PubChem CID | 2802 |
| DrugBank | DB01068 |
| UNII ID | 5PE9FDE8GB (ChemIDplus, GSRS) |
Target
Agency Approved
GABRA1
GABRA1
GABRA3
GABRA3
GABRA2
GABRA2
Organism
Homo sapiens
Gene name
GABRA1
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-1
Protein synonyms
GABA(A) receptor subunit alpha-1, GABA(A) receptor, alpha 1, gamma-aminobutyric acid (GABA) A receptor, alpha 1, gamma-aminobutyric acid type A receptor alpha1 subunit
Uniprot ID
Mouse ortholog
Gabra1 (14394)
gamma-aminobutyric acid receptor subunit alpha-1 (P62812)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Clonazepam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,160 documents
View more details
Safety
Black-box Warning
Black-box warning for: Klonopin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
48,694 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use